Ushbu ishga iqtibos qilgan ishlar

3 ta ish

Ish: A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

1. CAR-T cell combination therapy: the next revolution in cancer treatment

   Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa +8

   Sharh maqolaCAR-T cell therapy researchCancer Cell International20222 iqtibos

   ABIABI:AkademIndex/openalex/2022.review-article.000004

2. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives

   Muqadas Shahzadi, Hamad Rafique, Ahmad Waheed +4

   Sharh maqolaCAR-T cell therapy researchTherapeutic Advances in Vaccines and Immunotherapy20241 iqtibos

   ABIABI:AkademIndex/openalex/2024.review-article.000014

3. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083